ENDIA

Australia's largest study into the cause of type 1 diabetes. Recruitment to the study is now complete. Find out more at www.endia.org.au and Harry B.

Recruitment to the ENDIA Study has closed. The ENDIA (Environmental Determinants of Islet Autoimmunity) study is looking into what contributes to the development of Type 1 Diabetes in early childhood. Type 1 Diabetes in children is twice as common as it was 20 years ago. This is because our environment has changed and at-risk children are more likely to develop Type 1 Diabetes. If we can understan

d exactly what in the environment is harmful or protective, we can develop strategies to prevent Type 1 Diabetes. We believe that children are exposed to these environmental triggers very early in life, perhaps even before they are born. Accordingly, the ENDIA study has recruited 1511 participants across Australia from the pregnancy or up to 6 months of age that have a first-degree relative (i.e. baby's Mum, Dad or older sibling) with Type 1 Diabetes. ENDIA is an observational investigation and does not involve any study medications or treatments. Further information is available on the ENDIA website at www.endia.org.au. This research has been supported by JDRF Australia, JDRF-I, Australian Research Council Special Research Initiative in Type 1 Juvenile Diabetes and the Leona M. Helmsley Charitable Trust. Please note, comments and opinions made by others are not necessarily endorsed by the ENDIA Study Team. All content posted by the ENDIA Team has had ethical approval for public view. Thanks for your interest in finding the causes of Type 1 Diabetes!

30/05/2026

A very special shout out to 9-year-old Zidan who has completed his final ENDIA study visit.

From the very beginning of his life, he and his family have given their time, their data, their samples, and their commitment to help us understand development. This contribution is embedded into the research in ways that will matter for families for years to come.

To Zidan and his family — thank you. We hope you know that being part of something this important, for this long, is something truly worth being proud of. These years of participation are a gift to every family affected by type 1 diabetes.

Here's to you, Zidan. Wishing you all the very best for the future.

27/05/2026

The Australian Therapeutic Goods Administration (TGA) has approved Tzield (teplizumab) to delay the onset of stage 3 (symptomatic) .

Stage 2 means two or more islet autoantibodies (early markers) have been detected from a blood test and glucose levels are erratic ( ), but no symptoms are evident.

The progression of type 1 diabetes happens in stages. People with stage 2 T1D will gradually progress to stage 3 T1D, with the experience of symptoms ( , , and losing weight, more often). Elevated glucose levels require insulin treatment. This process can take place over months or years.

Studies of Tzield have proven to slow this progression by an average of 2 years. That's at least two years less of injections and finger pricks.

This is the first new therapy approved for T1D in over 100 years, since the discovery of .

Tzield involves an intravenous (IV) infusion. People must be aged 8 years or older and in stage 2 type 1 diabetes.

Read more on the Breakthrough T1D Australia website:

https://breakthrought1d.org.au/news/tzield-approved-in-australia/

25/05/2026

Hooray for Harvie. You’ve done it! You’ve completed your time with the ENDIA Study.

Harvie participated in the regional program, so here he is about to post off his final box packed with samples to nurse Sarah.

Is your participation medal real gold? Maybe not. But your time, support and contributions certainly are!

Thank you so much for everything you and your family have contributed to finding the causes of so that one day we may be able to find ways to prevent the condition from developing.

22/05/2026

The future of type 1 diabetes treatment may look different for every person 💙🔬

Could the path to T1D actually vary from p[erson to person — even when the end result looks the same? New research suggests yes.

Scientists studied cord blood — collected at birth — from children who later developed .

Instead of looking at genes directly, they looked at how genes were being switched on and off by the body's own chemistry.

They found two groups of children developed , but by completely different biological routes.

One group showed signs linked to immune activity. The other showed patterns connected to how the body manages and . And these signals were present at birth — before any symptoms appeared. Same diagnosis. Different journeys to get there. 🔍

This matters because it opens the door to treatments tailored to an individual's own biology — rather than treating all T1D the same way.

📖 Read more at: https://doi.org/10.1111/joim.70077

19/05/2026

Celebrating and thankful for every person who said yes to research.

18/05/2026

🌟 24 visits and 10 amazing years with Miss Addison!

This has completed her study visits with the ENDIA study cohort. That is an incredible commitment from Addison and her wonderful family, and we could not be more grateful. 💙

From her very first visit as a tiny baby to the amazing 10-year-old she is today, Addison has grown up as part of the ENDIA family — and what a journey it has been!

Every visit, every sample, and every moment of time her family has given is helping researchers better understand and how we might one day prevent it. What a truly remarkable gift to science and to future generations.

Thank you, Addison, and thank you to your family for your incredible dedication. You are the reason this research is possible. 🎉 And congratulations on reaching your first decade! Happy birthday.

14/05/2026

Awesome Alina has completed study visits with ENDIA. 🎉 A huge milestone for another of our incredible ENDIA families!

After years of dedication, curiosity, and so many samples collected along the way, amazing Alina has completed their final study visit with the ENDIA cohort. 🌟

From tiny baby to the wonderful child they are today — watching her grow through this journey has been an absolute privilege. Her family's commitment to understanding has been an incredible contribution to science that we hope will help generations to come.

To Alina, and every family who has given their time, their energy, and their trust to the ENDIA study — thank you. You are the heart of this research. 💙

12/05/2026

Happy International Nurses Day to our valued ENDIA Nurses and all those fabulous nurses who have helped contribute to the ENDIA Study!

www.endia.org.au

11/05/2026

Could immune "fingerprinting" help predict Type 1 diabetes before it develops? 🩸🔬

New research mapped immune profiles in children with T1D, their unaffected siblings, and unrelated children with no known conditions — and found something significant.

A type of immune cell called memory Tregs was elevated in both people diagnosed with and their siblings, compared to unrelated children with no known conditions.

To families reading this — this does not mean a sibling will develop . But it does suggest early immune differences may be detectable, which could one day lead to better and more personalised screening, monitoring and care.

Early days, but promising steps toward predicting and preventing diabetes in those with a greater chance of development 💙

📖 To read the the full study click on: https://doi.org/10.2337/db25-0161

For more information about screening in Australia for family members go to www.type1screen.org

Type1Screen Type1Screen

07/05/2026

Omega-3s in Pregnancy: Do supplements protect against infections linked to Type 1 Diabetes?

Omega-3 fatty acids — found in oily fish and fish oil supplements — are known for their anti-inflammatory properties, and there's been hope they might help protect children from early infections. This matters to the type 1 diabetes community because certain viruses, particularly coxsackieviruses, are suspected triggers for the disease.

This large study across Norway, Finland, and Denmark (77,000+ mother-child pairs) looked at whether mothers who consumed more omega-3 during pregnancy had children with fewer infections in the first three years of life.

The answer was essentially no. While there were marginal reductions in colds and stomach bugs in one dataset, a properly controlled trial found no benefit — and most importantly, there was no link between omega-3 intake and coxsackievirus infections specifically.

For our community, this study doesn't support omega-3 supplementation in pregnancy as a strategy for reducing infection-related diabetes triggers in children.

Read more at: https://doi.org/10.1016/j.tjnut.2026.101456

Address

Women's And Children's Hospital
Adelaide, SA
5006

Website

http://www.endia.org.au/

Alerts

Be the first to know and let us send you an email when ENDIA posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to ENDIA:

Shortcuts

Want your organization to be the top-listed Non Profit Organization in Adelaide?